Press Releases

 
Press Releases
Date Title and Summary View
Oct 18, 2016 SALT LAKE CITY, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that more than 40 of its employees are volunteering to support Project BioEYES, which is a science, technology, engineering and math (STEM) education program designed to teach K-1...
Oct 17, 2016
Oct 8, 2016 SALT LAKE CITY, Oct. 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced th...
Oct 7, 2016 SALT LAKE CITY, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and pers...
Oct 4, 2016 THE WOODLANDS, Texas and SALT LAKE CITY, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) and The US Oncology Net...
Oct 3, 2016 SALT LAKE CITY, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Note: the titles and abstract numbers have been corrected. Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that four poster presentations on Vectra® DA will be featured at the American College of Rheumatology...
Oct 3, 2016 SALT LAKE CITY, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that four poster presentations on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 11-16, 2016 in Washington, D...
Sep 29, 2016 SALT LAKE CITY, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Chip Parkinson will join the company in the newly created position of executive vice president (EVP) for Reimbursement Strategy. In this role, Mr. Parkinson will report to Mark C. Capone, president and CEO of Myriad Genetics with respo...
Sep 26, 2016 SALT LAKE CITY, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagno...
Sep 7, 2016 SALT LAKE CITY, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that researchers from the Institut Pasteur have published new landmark research from the Milieu Interieur Project relating to the abili...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase